COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,160 Articles (22,703 medRxiv, 8,457 bioRxiv)

Most recent first Previous |  Page 1032: Articles 10311-10320  | Next

Change in COVID-19 risk over time following vaccination with CoronaVac: A test-negative case-control study
Hitchings, M., Ranzani, O., Lind, M. L., Dorion, M., D'Agostini, T. L., Cardoso de Paula, R., Pereira de Paula, O. F., Moura de Villela, E. F., Scaramuzzini Torres, M. S., Barbosa de Oliveira, S., Schulz, W., Almiron, M., Said, R., de Oliveira, R. D., da Silva, P. V., de Araujo, W. N., Gorinchteyn, J. C., Dean, N. E., Andrews, J. R., Cummings, D. A., Ko, A. I., Croda, J.
10.1101/2021.12.23.21268335 — Posted: 2021-12-24
Population immunity to SARS-CoV-2 in US states and counties due to infection and vaccination, January 2020-November 2021
Klaassen, F., Chitwood, M. H., Cohen, T., Pitzer, V. E., Russi, M., Swartwood, N. A., Salomon, J. A., Menzies, N. A.
10.1101/2021.12.23.21268272 — Posted: 2021-12-24
Sharp Increases in Drug Overdose Deaths Among High-School-Age Adolescents During the US COVID-19 Epidemic and Illicit Fentanyl Crisis
Friedman, J., Godvin, M., Shover, C., Gone, J. P., Hansen, H., Schriger, D.
10.1101/2021.12.23.21268284 — Posted: 2021-12-24 Discussion: Onsite
Neutralising antibody activity against SARS-CoV-2 variants, including Omicron, in an elderly cohort vaccinated with BNT162b2
Newman, J., Thakur, N., Peacock, T. P., Bialy, D., Elreafey, A. M., Bogaardt, C., Horton, D. L., Ho, S., Kankeyan, T., Carr, C., Hoschler, K., Barclay, W. S., Amirthalingam, G., Brown, K., Charleston, B., Bailey, D.
10.1101/2021.12.23.21268293 — Posted: 2021-12-24
Neutralizing antibodies to SARS-CoV-2 Omicron variant after 3rd mRNA vaccination in health care workers and elderly subjects and response to a single dose in previously infected adults
Haveri, A., Solastie, A., Ekström, N., Österlund, P., Nohynek, H., Nieminen, T., Palmu, A. A., Melin, M.
10.1101/2021.12.22.21268273 — Posted: 2021-12-24
Three doses of the BNT162b2 vaccine confer neutralising antibody capacity against the SARS-CoV-2 B.1.1.529 (Omicron) variant of concern
Arien, K. K., Heyndrickx, L., Michiels, J., Vereecken, K., Van Lent, K., Coppens, S., Pannus, P., Martens, G. A., Van Esbroeck, M., Goossens, M. E., Marchant, A., Bartholomeeusen, K., Desombere, I.
10.1101/2021.12.23.21268316 — Posted: 2021-12-24
Echinacea as a Potential Force against Coronavirus Infections? A Mini-Review of Randomized Controlled Trials in Adults and Children
Nicolussi, S., Ardjomand-Woelkart, K., Stange, R., Gancitano, G., Klein, P., Ogal, M.
10.1101/2021.12.23.21267893 — Posted: 2021-12-24 Discussion: Onsite
Infrared spectroscopy enables rapid, robust, portable COVID-19 saliva screening based on pathophysiological response to SARS-CoV-2
Kazmer, S., Hartel, G., Robinson, H., Richards, R. S., Yan, K., Van Hal, S. J., Chan, R., Hind, A., Bradley, D., Zieschang, F., Rawle, D. J., Le, T. T., Reid, D. W., Suhrbier, A., Hill, M. M.
10.1101/2021.12.22.21268265 — Posted: 2021-12-24
Saliva swabs are the preferred sample for Omicron detection
Marais, G. J. K., Hsiao, N.-y., Iranzadeh, A., Doolabh, D., Enoch, A., Chu, C. Y., Williamson, C., Brink, A., Hardie, D. R.
10.1101/2021.12.22.21268246 — Posted: 2021-12-24 Discussion: Onsite
Serum anti-Spike antibody titers before and after heterologous booster with mRNA-1273 SARS-CoV-2 vaccine following two doses of inactivated whole-virus CoronaVac vaccine
Sinto, R., Utomo, D., Suwarti, S., Nelwan, E. J., Surendra, H., Natasha, C., Fransiska, F., Theresia, D., Ranitria, A. F., Subekti, D., Nuraeni, N., Handayani, W., Rahardjani, M., Baird, J. K., Dunachie, S., Shankar, A. H., Hamers, R. L.
10.1101/2021.12.24.21268360 — Posted: 2021-12-24

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).